Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

erm loan B facility.
  • In November 2008, Royalty Pharma raised US$262 million of private equity.
  • In May 2008, Royalty Pharma raised a US$150 million senior unsecured fixed rate term loan.
  • In May 2008, Royalty Pharma raised a US$150 million incremental senior secured term loan B facility.
  • In December 2007, Royalty Pharma raised a US$700 million incremental secured term loan B facility.
  • In October 2007, Royalty Pharma raised a US$400 million term loan B facility swapped to a fixed rate.
  • In May 2007, Royalty Pharma raised a US$1,400 million term loan B facility.
  •  

    APPENDIX IV: Basis for statement about value of Tysabri Royalty implied by the Tysabri TransactionAn estimate of the value of the Tysabri Royalty implied by the Tysabri Transaction can be calculated principally by making assumptions around the percentage of the economic value of the Pre-Restructuring Tysabri Participation acquired by Biogen in the Tysabri Transaction, through which it acquired the Disposed Tysabri Interest (the percentage being the "Disposed Tysabri Percentage").

    Based on an assumed value for the Disposed Tysabri Interest, one can infer the value of the Tysabri Royalty. Based on an assumed value for the Tysabri Royalty, it is also possible to infer an enterprise valuation for Elan as a whole by making an assumption about the value of Elan's other non-cash assets and attributes. Royalty Pharma ascribes minimal value to these other assets as discussed elsewhere in this announcement.

    Assumption on Disposed Tysabri Percentage

    The Disposed Tysabri Percentage can be estimated by comparing, on an annual basis, forecasts for the profit that would have accrued to Elan under the Pre-Restructuring Tysabri Participation (before the Tysabri Transaction) and the profit that will accrue to Elan under the residual Tysabri Royalty (following the Tysabri Transaction).

    Royalty Pharma has prepared an
    '/>"/>

    SOURCE RP Management, LLC
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
    2. Cowen Healthcare Royalty Partners Raises $1 Billion
    3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
    4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
    5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
    6. AVANIR Pharmaceuticals To participate in two conferences in March
    7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
    8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
    9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
    10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
    11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
    (Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
    (Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
    (Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
    Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
    ... Yves Lionel Assant is,the new Chairman of Gerresheimer,s ... was already a member of the Supervisory Board. ... position for personal reasons. He,remains a member of ... & life science supply and services,company with market ...
    ... Stephen Simes, chief executive,officer of BioSante Pharmaceuticals, ... be featured in an exclusive interview with, http://www.wallst.net ... EDT. The interview,will be posted on http://www.wallst.net ... The interview will cover topics including BioSante,s ...
    ... Calif., Sept. 24 Today, the rights ... utilize PARI,s,eFlow electronic nebulizer for aerosol delivery ... of Corus Pharma in,August 2006, this is ... eFlow is featured prominently in the development ...
    Cached Biology Technology:WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals 2Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca 2
    (Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
    (Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" report ... One major trend upcoming in this ... biomedical applications. Chemical sensors help in recording of patient ...
    (Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this ... technology, it is important to upgrade biometric solutions to ...
    Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... the Sundarbans, resulting in as much as 200m of coast ... (11th Jan) in Remote Sensing by scientists from ... development thrives, and global temperature continues to rise, natural protection ... rates. This will inevitably lead to species loss in this ...
    ... W. Finberg, MD, the Richard M. Haidack Professor of ... University of Massachusetts Medical School, is lead investigator on ... predicting how the influenza virus changes and evolves in ... This approach has promise for becoming a pivotal tool ...
    ... cells can be grown on biocompatible scaffolds to form ... repair and regeneration of damaged or diseased tissue. However, ... a specific pattern or alignment. An innovative method for ... tissue architectures is described in an article in ...
    Cached Biology News:Bengali forests are fading away 2